Lauren Riker, Senior Vice President, Finance at Pacira BioSciences, Inc. (NASDAQ:PCRX), filed a Form 4 on November 17, 2026, disclosing the disposition of all directly held common stock, restricted stock units, and stock options in connection with the consummation of a merger with Viatris Inc.

Key Highlights

  • Merger completed November 17, 2026: Peach Purchaser Sub Inc., a Viatris subsidiary, completed a cash tender offer and merged with and into Pacira BioSciences, with Pacira continuing as the surviving corporation and a wholly owned subsidiary of Viatris.
  • Offer price of $36.50 per share: Each share of Pacira common stock was converted into the right to receive $36.50, net of applicable withholding taxes and without interest, at the effective time of the merger.
  • 6,881.242 shares disposed at $36.50: Riker's directly held common shares were disposed of under transaction code U, reducing her beneficial ownership to zero.
  • 55,403 RSU shares canceled at $36.50: Outstanding restricted stock unit awards, whether vested or unvested, were canceled and converted into the right to receive cash equal to the number of shares issuable multiplied by the offer price.
  • Eleven stock option grants canceled: All outstanding options were canceled at the effective time; options with an exercise price at or above $36.50 per share received no consideration.
  • Post-transaction beneficial ownership is zero: Following all reported transactions, Riker holds no shares of Pacira BioSciences common stock directly.

Riker's Holdings Extinguished at Pacira-Viatris Merger Effective Time

According to the filing, the transactions reported by Lauren Riker, Senior Vice President, Finance, arose entirely from the Agreement and Plan of Merger dated October 8, 2026, among Pacira BioSciences, Inc., Viatris Inc., and Peach Purchaser Sub Inc. On November 17, 2026, Peach Purchaser Sub Inc. consummated a cash tender offer to purchase all outstanding shares of Pacira common stock at $36.50 per share, after which it merged with and into Pacira, with Pacira surviving as a wholly owned subsidiary of Viatris.

The filing reports two common stock transactions. First, 6,881.242 shares were disposed of under transaction code U at $36.50 per share, reducing Riker's directly held shares to 55,403. Second, all 55,403 remaining shares were disposed of under transaction code D at $36.50, leaving her with zero direct beneficial ownership. The filing attributes both dispositions to the merger mechanics, under which each share was converted into the right to receive the offer price at the effective time.

The filing further discloses that 55,403 restricted stock unit shares were canceled and converted into the right to receive cash equal to the total shares issuable under those RSUs multiplied by $36.50, subject to applicable tax withholdings. In addition, eleven stock option grants with exercise prices ranging from $38.35 to $81.00 per share were each canceled. The filing states that options with a per-share exercise price greater than or equal to the offer price were canceled with no consideration payable. Options with exercise prices below $36.50, specifically those priced at $36.50 or lower, would have been eligible for cash consideration equal to the spread multiplied by the number of underlying shares, subject to tax withholdings.

What Was Disclosed

Lauren Riker's Form 4 reports the full elimination of her beneficial ownership in Pacira BioSciences common stock, RSUs, and stock options on November 17, 2026, as a direct result of the merger between Pacira and a Viatris subsidiary at $36.50 per share.